Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 14/20 | 1.00 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10621413 | 0.83 | FDPS (0.71) | FDPSPDE3ATBXAS1 | |
| SCHEMBL10622017 | 0.79 | FDPS (0.65) | FDPSPDE3ATBXAS1 | |
| SCHEMBL9460152 | 0.79 | FDPS (0.65) | FDPSTBXAS1ALOX15 | |
| SCHEMBL9460227 | 0.77 | FDPS (0.61) | FDPSTBXAS1ALOX15 | |
| SCHEMBL3074784 | 0.77 | FDPS (0.61) | FDPSTBXAS1ALOX15 | |
| SCHEMBL9460123 | 0.74 | FDPS (0.57) | FDPS | |
| SCHEMBL10829478 | 0.73 | FDPS (0.58) | FDPSTBXAS1ALOX15 | |
| SCHEMBL16673143 | 0.72 | FDPS (0.55) | FDPSTBXAS1ALOX15 | |
| Phosphoric Acid SCHEMBL5074764 | 0.72 | FDPS (0.56) | FDPSTBXAS1ALOX15 | |
| SCHEMBL12909224 | 0.71 | FDPS (0.56) | FDPSTBXAS1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915239-B2 | Treating lameness with an osseous and/or articular component which appear in a person or animal not suffering from fractures or arthritis; horses; veterinary medicine; bone disorders, osteoarthritis | CEVA SANTE ANIMALE (FR) | 2011-03-29 | — | — | US | claimed |
| US-20060183717-A1 | Process for treating lameness with an osseous, articular or osteoarticular component in human or veterinary medicine, comprising the administration of a bisphosphonic acid derivative | CEVA SANTE ANIMALE | 2006-08-17 | — | — | US | claimed |
| EP-1689744-A1 | ANTIRESORPTIVE MUTUAL SALT OF RALOXIFENE AND BISPHOSPHONIC ACID | Hanmi Pharm. Co., Ltd. (KR) | 2006-08-16 | — | — | EP | claimed |
| EP-1117410-B1 | USE OF BISPHOSPHONIC ACID DERIVATIVES FOR PREPARING A MEDICINE FOR TREATING LAMENESS | CEVA SANTE ANIMALE (FR) | 2005-12-28 | — | — | EP | claimed |
| WO-2005047282-A1 | ANTIRESORPTIVE MUTUAL SALT OF RALOXIFENE AND BISPHOSPHONIC ACID | HANMI PHARM. CO., LTD. (KR) | 2005-05-26 | — | — | WO | claimed |
| US-20040110726-A1 | Process for treating lameness administration of a bisphosphonic acid derivative | CEVA SANTE ANIMALE | 2004-06-10 | — | — | US | claimed |
| US-6696429-B2 | ESPECIALLY DUE TO OSTEOARTHROSIS, OSTEOCHONDROSIS, NAVICULAR DISEASE OR ENTHESOPATHY OF THE BONY INSERTIONS OF THE TENDONS, OF THE LIGAMENTS, OR OF THE APONEUROSIS, PARTICULARLY IN HORSES | CEVA SANTE ANIMALE (FR) | 2004-02-24 | — | — | US | claimed |
| EP-1296689-A2 | METHOD OF ADMINISTERING BISPHOSPHONATES | Novartis AG (CH) | 2003-04-02 | — | — | EP | claimed |
| US-20030032627-A1 | Process for treating lameness by administration of a bisphosphonic acid derivative | SANOFI SANTE NUTRITION ANIMALE | 2003-02-13 | — | — | US | claimed |
| WO-2001097788-A2 | METHOD OF ADMINISTERING BISPHOSPHONATES | NOVARTIS AG (CH) | 2001-12-27 | — | — | WO | claimed |
| EP-0623347-B1 | Use of bisphosphoric acid derivatives for the manufacture of a medicament to improvement bone repair | SANOFI SYNTHELABO (FR) | 2001-10-31 | — | — | EP | claimed |
| US-20010006960-A1 | PROCESS FOR TREATING LAMENESS BY ADMINISTRATION OF A BISPHOSPHONIC ACID DERIVATIVE | CEVA SANTE ANIMALE (FR) | 2001-07-05 | — | — | US | claimed |
| EP-0998934-A1 | REMEDIES FOR INTRAMEDULLARY DISEASES | TORAY INDUSTRIES, INC. (JP) | 2000-05-10 | — | — | EP | claimed |
| EP-0275821-A1 | Substituted alkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | claimed |
| US-8772268-B2 | Bisphosphonamidate prodrugs and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772268-B2 | Bisphosphonamidate prodrugs and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130090311-A1 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-11 | — | — | US | disclosed |
| US-4939130-A | Substituted alkanediphosphonic acids and pharmaceutical use | CIBA-GEIGY CORPORATION (US) | 1990-07-03 | — | — | US | disclosed |
| US-4777163-A | BONE DISORDERS, RHEUMATIC DISEASES | BOEHRINGER MANNHEIM GMBH (DE) | 1988-10-11 | — | — | US | disclosed |
| EP-0258618-A2 | Diphosphonic acid derivatives, process for their preparation and medicines containing those compounds | Roche Diagnostics GmbH (DE) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183717-A1 | Process for treating lameness with an osseous, articular or osteoarticular component in human or veterinary medicine, comprising the administration of a bisphosphonic acid derivative | SLC16A1, SLC26A4, SLCO4C1 | FDPS 703/4885BTN3A1 198/4885PDE3A 4038/4885 |
| US-20030032627-A1 | Process for treating lameness by administration of a bisphosphonic acid derivative | SLC16A1, CLIC1, SLC16A3 | FDPS 1138/4885BTN3A1 226/4885PDE3A 3753/4885 |
| US-20010006960-A1 | PROCESS FOR TREATING LAMENESS BY ADMINISTRATION OF A BISPHOSPHONIC ACID DERIVATIVE | SLC16A1, CLIC1, SLC16A3 | FDPS 1138/4885BTN3A1 226/4885PDE3A 3753/4885 |
| US-20130090311-A1 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF | BPGM, PHPT1, PFKFB2 | FDPS 48/4885BTN3A1 1790/4885PDE3A 1171/4885 |
| US-20040110726-A1 | Process for treating lameness administration of a bisphosphonic acid derivative | SLC16A1, SLC16A3, CLIC1 | FDPS 1099/4885BTN3A1 285/4885PDE3A 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.